Steven Woloshin, MD
Title(s)
Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine
Department(s)
The Dartmouth Institute
Medicine
Community and Family Medicine
Education
Dartmouth Medical School, MS 1996
Boston University School of Medicine, MD 1987
Boston University, BA 1987
Programs
The Dartmouth Institute for Health Policy and Clinical Practice
Contact Information
Dartmouth Medical School
HB 7900
Hanover NH 03755
Phone: 603 646 5672
Email: steven.woloshin@dartmouth.edu
Professional Interests
Dr. Woloshin's research interest is in learning how to enhance the quality of medical communication to the public, patients, physicians and policymakers. His work (in collaboration with Dr. Lisa Schwartz) has 2 main approaches: improving the quality of messages presenting health information to people, and preparing audiences to make sense of the messages they receive. His main focus is on the communication of medical statistics and information about the benefits and harms of screening and prescription drugs.
Responding to public health challenges of medical advice from social media influencers. Patient and Physician Perspectives on Using Risk Prediction to Support Breast Cancer Surveillance Decision Making. Less is more for patients, practitioners, public and planet: a taxonomy for the harms of too much medicine. Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines. Trends in use of the new MeSH term "overdiagnosis": A bibliometric review. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22. What evidence is required to justify the NHS Health Check programme? Alternative Presentations of Overall and Statistical Uncertainty for Adults' Understanding of the Results of a Randomized Trial of a Public Health Intervention: Parallel Web-Based Randomized Trials. Corrigendum to "Tobacco Product Use and Functionally Important Respiratory Symptoms Among US Adolescents/Young Adults" [Acad Pediatr. 2022; 22(6):1006-1016]. Physician-Patient Communication about Novel Drugs and High-Risk Medical Devices. |
|